A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
Abstract A priori use of mathematical modeling and simulation to predict outcomes from incomplete adherence or reduced frequency dosing strategies may mitigate the risk of clinical trial failure with HIV pre‐exposure prophylaxis regimens. We developed a semi‐physiologic population pharmacokinetic mo...
Main Authors: | Erick Leung, Mackenzie L. Cottrell, Craig Sykes, Nicole White, Angela D. M. Kashuba, Julie B. Dumond |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13042 |
Similar Items
-
Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
by: Sara Iannuzzi, et al.
Published: (2021-07-01) -
Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01) -
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01) -
Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
by: Rashmee Patil, et al.
Published: (2015-01-01) -
A New Combined Antiretroviral Therapy In Adolescents With HIV: Bictegravir/Emtricitabine/Tenofovir Alafenamide
by: Neslihan Mete Atasever, et al.
Published: (2024-12-01)